CJC-1295 (No DAC / Modified GRF 1-29)
← Back to LibraryCompound Profile
CJC-1295 (No DAC / Modified GRF 1-29) is reviewed here for growth-hormone signaling and recovery context.
Research Summary
Safety notices, literature searches, limited protocol data
Growth-hormone signaling, Recovery, Body composition
Target context: GHRH
Limited, unclear, or affected by safety flags.
Claims need extra caution because evidence is thin or safety flags apply.
Route(s)
Subcutaneous
Typical dose
100mcg
Dosing window
Pre-Bed Fasted
Receptor / target
GHRH
Properties
GH Secretagogue
Pre-mixed
No
How CJC-1295 works in the body
CJC-1295 is discussed through the growth-hormone pathway: GHRH-style signaling, pituitary response, liver IGF-1, and downstream muscle context. Tap a glowing point to see the pathway.
This is here to help you learn and is not medical advice. Evidence labels show how much human research stands behind each effect.
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 100mcg once daily | Administered right before bed. Must be fasted for 2+ hours. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 100 mcg 1x Daily | At bedtime fasted. |
| Weeks 3-4 | 150 mcg 1x Daily | At bedtime fasted. |
| Weeks 5-6 | 200 mcg 1x Daily | At bedtime fasted. |
| Weeks 7-12 | 250-300 mcg 1x Daily | At bedtime fasted. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 2 (Low-Dose / Anti-Aging)
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 100mcg 1x Daily | At bedtime fasted. |
| Weeks 5-12 | 150mcg 1x Daily | At bedtime fasted. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 3 (2x/Day Protocol)
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 100 mcg 2x/day | AM/PM fasted. |
| Weeks 2-4 | 200 mcg 2x/day | AM/PM fasted. |
| Weeks 5-8 | 300 mcg 2x/day | AM/PM fasted. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 4 (3x/Day Protocol)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-3 | 150 mcg 3x/day | AM/PM fasted, MidDay post meal. |
| Days 4-7 | 200 mcg 3x/day | AM/PM fasted, MidDay post meal. |
| Weeks 2-3 | 300 mcg 3x/day | AM/PM fasted, MidDay post meal. |
| Weeks 4-6 | 400 mcg 3x/day | AM/PM fasted, MidDay post meal. |
| Weeks 7-12 | 500 mcg 3x/day | AM/PM fasted, MidDay post meal. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | FDA safety-risk context or unapproved compounded-use warning is attached to this entry; no FDA-approved human label was identified for this compound/page context. |
|---|---|
| Where studied | Studied around pituitary GH signaling, IGF-1 response, body-composition endpoints, growth-hormone deficiency models, or discontinued anabolic programs depending on the compound. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: GHRH. Route(s): Subcutaneous. Dosing window on page: Pre-Bed Fasted. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty. |
Source-linked findings
- GH-axis compounds are best interpreted through pituitary physiology, IGF-1 response, pulse timing, and metabolic adverse effects rather than dose escalation alone.
- Evidence strength ranges from approved labels for specific agents to sparse or discontinued development programs for research peptides.
- FDA lists CJC-1295 among withdrawn nominated bulk substances with potential significant safety risks, limited clinical data, and serious adverse events reported.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-12, 100mcg once daily; Alternative Titration 1: Weeks 1-2, 100 mcg 1x Daily.
- Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty.
- Monitor IGF-1 response, fasting glucose/A1c, edema, carpal-tunnel symptoms, blood pressure, sleep apnea, and malignancy history.
Selected medical sources
Independent evidence
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Active cancer or history of malignancy: GH elevation accelerates cell proliferation; contraindicated in any hormone-sensitive or actively growing tumor.
- High risk of tumor growth: subjects with pre-cancerous conditions, strong family history of growth-hormone sensitive cancers, or elevated cancer biomarkers.
- Active acromegaly or other conditions involving excess endogenous GH or IGF-1.
- Diabetic ketoacidosis: acute metabolic instability precludes GH-axis manipulation.
- Uncontrolled diabetes mellitus or significant insulin resistance: IGF-1 elevation from GH stimulation worsens glucose metabolism.
- Pregnancy: safety not established; GH axis stimulation during pregnancy is not advised.
- Breastfeeding: safety not established.
- Known hypersensitivity to CJC-1295 or any formulation excipients.
- Concurrent use with CJC-1295 DAC, tesamorelin, sermorelin, or HGH 191aa: direct GHRH receptor competition or redundant GH axis overstimulation.
- Concomitant glucocorticoid therapy at high doses: glucocorticoids blunt pituitary GH response and inhibit IGF-1 production.
- Disruption of the hypothalamic-pituitary axis (e.g., pituitary adenoma, cranial radiation history): GHRH-R stimulation may be unpredictable.
- Pediatric use in children with closed growth plates: inappropriate bone growth stimulation risk.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Head rush and transient facial flushing immediately following injection: caused by acute GH pulse-induced vasodilation; typically resolves within 15-30 minutes.
- Water retention and mild peripheral edema: GH-mediated sodium and fluid retention; most pronounced in the first 2-4 weeks and in higher-dose protocols.
- Mild fatigue or lethargy: transient, typically occurs within 30-60 minutes post-injection; associated with the acute GH pulse.
- Headache: related to vasodilation from the GH pulse; common in the first 1-2 weeks; diminishes with continued use.
- Dizziness or lightheadedness: transient; associated with acute GH-mediated vasodilation.
- Tingling or numbness in hands and feet: paresthesia from GH-related fluid shifts; more common at higher doses.
- Vivid dreams: GH elevation during the nocturnal sleep cycle intensifies REM-phase dream vividness.
- Joint stiffness: GH-mediated fluid in periarticular tissue; common at higher dose levels.
- Mild hypoglycemia: possible when combined with fasting and a GHRP; GH pulse temporarily shifts glucose partitioning toward fat oxidation.
- Increased appetite: modest; GH elevation has mild orexigenic effects.
- Mild transient blood pressure elevation: secondary to GH-induced sodium retention; generally within normal range.
- Injection site irritation: redness, swelling, or discomfort at subcutaneous administration site.
- Pituitary desensitization with continuous use beyond cycle length: GH response attenuates if 12-16 week cycle limit is exceeded without washout.
- Blunted efficacy from insufficient fasting: eating carbs or fats within 2 hours of injection significantly reduces or eliminates the GH pulse; not a side effect per se but the primary compliance failure point.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: